乳腺癌保乳术后大分割放疗的研究进展

国际肿瘤学杂志››2018,Vol. 45››Issue (8): 570-573.doi:10.3760/cma.j.issn.1673-422X.2018.09.013

乳腺癌保乳术后大分割放疗的研究进展

郑林晶，董银萍，胡兵，夏重升，李宝生，黄伟

250200 济南大学 betway.com 医学与生命科学学院（郑林晶、董银萍、胡兵）；济宁医学院附属医院肿瘤科（郑林晶、夏重升）；山东大学附属山东省肿瘤医院放疗六病区（李宝生、黄伟）

出版日期:2018-09-08发布日期:2018-11-15
通讯作者:黄伟 E-mail:alvinbird@163.com
基金资助:

国家自然科学基金（81773232、81530060）；山东省自然科学基金（ZR2015QZ09）；泰山学者建设工程（ts20120505）

Research progress of hypofractionated whole breast irradiation after breast conserving surgery

Zheng Linjing, Dong Yinping, Hu Bing, Xia Chongsheng, Li Baosheng, Huang Wei

School of Medicine and Life Sciences, University of Ji′nan Shandong Academy of Medical Sciences, Ji′nan 250200, China; Department of Oncology, Affiliated Hospital of Jining Medical University, Jining 272000, China

Online:2018-09-08Published:2018-11-15
Contact:Huang Wei E-mail:alvinbird@163.com
Supported by:

National Natural Science Foundation of China (81773232, 81530060); Natural Science Foundation of Shandong Province of China (ZR2015QZ09); Taishan Scholar Construction Project (ts20120505)

摘要/Abstract

摘要：乳腺癌保乳术联合大分割放疗已成为早期乳腺癌治疗的新模式。临床研究表明乳腺癌的α/β值比一般肿瘤低，更适合大分割放疗。大分割放疗具有良好的经济效益，多项经典随机对照研究长期随访结果表明，全乳腺大分割放疗是有效和安全的。随着大分割放疗的广泛应用，这项技术也逐渐被拓展到区域淋巴结照射、乳房切除术后放疗以及乳腺导管原位癌的放疗中。

关键词:乳腺肿瘤,放射疗法,治疗效果,保乳术,不良反应

Abstract:Hypofractionated radiotherapy after breast conserving surgery has become a new standard treatment of early breast cancer. Clinical researches show that α/β value of breast cancer is lower than that of other tumors, and the breast cancer is more suitable for hypofractionated radiotherapy. Hypofractionated radiotherapy has good economic benefits, and longterm followup results from a number of classical randomized controlled studies have shown that hypofractionated whole breast irradiation is effective and safe. With the extensive application of hypofractionated irradiation, this technology has been gradually extended to regional nodal irradiation, postmastectomy radiotherapy and breast ductal carcinoma in situ.

Key words:Breast neoplasms,Radiotherapy,Treatment effect,Breast conserving surgery,Sideeffects

郑林晶，董银萍，胡兵，夏重升，李宝生，黄伟. 乳腺癌保乳术后大分割放疗的研究进展[J]. 国际肿瘤学杂志, 2018, 45(8): 570-573.

Zheng Linjing, Dong Yinping, Hu Bing, Xia Chongsheng, Li Baosheng, Huang Wei. Research progress of hypofractionated whole breast irradiation after breast conserving surgery[J]. Journal of International Oncology, 2018, 45(8): 570-573.

参考文献

［1］ Qi XS, White J, Li XA. Is α/β for breast cancer really low?［J］. Radiother Oncol, 2011, 100(2): 282288. DOI: 10.1016/j.radonc.2011.01.010. ［2］ Yarnold J, Ashton A, Bliss J, et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: longterm results of a randomised trial［J］. Radiother Oncol, 2005, 75(1): 917. DOI: 10.1016/j.radonc.2005.01.005. ［3］ Owen JR, Ashton A, Bliss JM, et al. Effect of radiotherapy fraction size on tumour control in patients with earlystage breast cancer after local tumour excision: longterm results of a randomised trial［J］. Lancet Oncol, 2006, 7(6): 467471. DOI: 10.1016/S14702045(06)706994. ［4］ START Trialists′ Group, Bentzen SM, Agrawal RK, et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial［J］. Lancet Oncol, 2008, 9(4): 331341. DOI: 10.1016/S14702045(08)700779. ［5］ Haviland JS, Owen JR, Dewar JA, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10year followup results of two randomised controlled trials［J］. Lancet Oncol, 2013, 14(11): 10861094. DOI: 10.1016/S14702045(13)703863. ［6］ Yarnold J. Hypofractionation, rationale, current status and futuredirections［R］. ASTRO′s 56th Annual Meeting. San Francisco, CA: Fairfax, VA. 2014: 1417. ［7］ Versmessen H, VinhHung V, Van Parijs H, et al. Healthrelated quality of life in survivors of stage ⅠⅡ breast cancer: randomized trial of postoperative conventional radiotherapy and hypofractionated tomotherapy［J］. BMC Cancer, 2012, 12: 495. DOI: 10.1186/1471240712495. ［8］ Greenup RA, Camp MS, Taghian AG, et al. Cost comparison of radiation treatment options after lumpectomy for breast cancer［J］. Ann Surg Oncol, 2012, 19(10): 3275 3281. DOI: 10.1245/s1043401225465. ［9］ Ciafre AC, Torices JM, Jordá E, et al. EP1143 Hypofractionated vs conventionally fractionated breast radiotherapy: Economic consequences［R］. ESTRO 36. Ireland: Elsevier Ltd. 2017: S622. ［10］ Niska JR, Keole SR, Pockaj BA, et al. Choosing wisely after publication of level Ⅰ evidence in breast cancer radiotherapy［J］. Breast Cancer (Dove Med Press): 2018, 10: 3137. DOI: 10.2147/BCTT.S153117. ［11］ Whelan T, MacKenzie R, Julian J, et al. Randomized tiral of breast irradiation schedules after lumpectomy for women with lymph nodenegative breast cancer［J］. J Natl Cancer Inst, 2002, 94(15): 11431150. DOI: 10.1093/jnci/94.15.1143. ［12］ Whelan TJ, Pignol JP, Levine MN, et al. Longterm results of hypofractionated radiation therapy for breast cancer［J］. N Engl J Med, 2010, 362(6): 513520. DOI: 10.1056/NEJMoa0906260. ［13］ START Trialists′ Group, Bentzen SM, Agrawal RK, et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised thail［J］. Lancet, 2008, 371(9618): 10981107. DOI: 10.1016/S01406736(08)603487. ［14］ Swanick CW, Lei X, Shaitelman SF, et al. Longitudinal analysis of patientreported outcomes and cosmesis in arandomized trial of conventionally fractionated versus hypofractionated wholebreast irradiation［J］. Cancer, 2016, 122(18): 28862894. DOI: 10.1002/cncr.30121. ［15］ Early Breast Cancer Trialists′ Collaborative Group (EBCTCG), Correa C, McGale P, et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast［J］. J Natl Cancer Inst Monogr, 2010, 2010(41): 162177. DOI: 10.1093/jncimonographs/lgq039. ［16］ Lalani N, Paszat L, Sutradhar R, et al. Longterm outcomes of hypofractionation versus conventional radiation therapy after breastconserving surgery for ductal carcinoma in situ of the breast［J］. Int J Radiat Oncol Biol Phys, 2014, 90(5): 10171024. DOI: 10.1016/j.ijrobp.2014.07.026. ［17］ Rakovitch E, Narod SA, NofechMoses S, et al. Impact of boost radiation in the treatment of ductal carcinoma in situ: a populationbased analysis［J］. Int J Radiat Oncol Biol Phys, 2013, 86(3): 491497. DOI: 10.1016/j.ijrobp.2013.02.031. ［18］ Ragaz J, Olivotto IA, Spinelli JJ, et al. Locoregional radiation therapy in patients with highrisk breast cancer receiving adjuvant chemotherapy: 20year results of the British Columbia randomized trial［J］. J Natl Cancer Inst, 2005, 97(2): 116126. DOI: 10.1093/jnci/djh297. ［19］ Danish Breast Cancer Cooperative Group, Nielsen HM, Overgaard M, et al. Study of failure pattern among highrisk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: longterm results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomised studies［J］. J Clin Oncol, 2006, 24(15): 22682275. DOI: 10.1200 / JCO.2005.02.8738. ［20］ Galecki J, HicerGrzenkowicz J, GrudzieńKowalska M, et al. Radiationinduced brachial plexopathy and hypofractionated regimens in adjuvant irradiation of patients with breast cancer—a review［J］. Acta Oncol, 2006, 45(3): 280284. DOI: 10.1080/02841860500371907. ［21］ Badiyan SN, Shah C, Arthur D, et al. Hypofractionated regional nodal irradiation for breast cancer: examining the data and potential for future studies［J］. Radiother Oncol, 2014, 110(1): 3944. DOI: 10.1016/j.radonc. 2013.12.006. ［22］ Coles CE, Griffin CL, Kirby AM, et al. Partialbreast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5year results from a multicentre, randomised, controlled, phase 3, noninferiority trial［J］. Lancet, 2017, 390(10099): 10481060. DOI: 10.1016/S01406736(17)311455. ［23］ Olivotto IA, Whelan TJ, Parpia S. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using threedimensional conformal external beam radiation therapy［J］. J Clin Oncol, 2013, 31(32): 40384045. DOI: 10.1200/JCO.2013.50.5511. ［24］ Ashworth A, Kong W, Whelan T, et al. A populationbased study of the fractionation of postlumpectomy breast radiation therapy［J］. Int J Radiat Oncol Biol Phys, 2013, 86(1): 5157. DOI: 10.1016/j.ijrobp.2012.12.015. ［25］ Peterson D, Truong PT, Parpia S, et al. Predictors of adverse cosmetic outcome in the RAPID Trial: an exploratory analysis［J］. Int J Radiat Oncol Biol Phys, 2015, 91(5): 968976. DOI: 10.1016/j.ijrobp.2014.12.040. ［26］ Smith BD, Bentzen SM, Correa CR, et al. Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidencebased guideline［J］. Int J Radiat Oncol Biol Phys, 2011, 81(1): 5968. DOI: 10.1016/j.ijrobp.2010.04.042.

[1]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[3]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇.信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[4]	萨蔷, 徐航程, 王佳玉.乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[5]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙.肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[6]	严爱婷, 王翠竹, 刘春桂, 鲁小敏.卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[7]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵.寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[8]	李济时, 陆钊群, 刘俊茹, 吕建勋, 陈霜, 沈琳, 徐志渊, 吴平安.新辅助放疗联合部分喉切除术治疗喉滑膜肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(2): 123-125.
[9]	陈波光, 王苏贵, 张永杰.血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[10]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会.中国食管癌放射治疗指南（2023年版）[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20.
[11]	高新雨, 李振江, 孙洪福, 韩丹, 赵倩, 刘成新, 黄伟.基于MR加速器的MR引导放疗在食管癌患者中的临床应用[J]. 国际肿瘤学杂志, 2024, 51(1): 37-42.
[12]	顾花艳, 朱腾, 郭贵龙.乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[13]	王景, 许文婷.中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[14]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英.HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[15]	崔腾璐, 吕璐, 孙鹏飞.放疗联合免疫治疗在头颈部鳞状细胞癌治疗中的应用[J]. 国际肿瘤学杂志, 2023, 50(9): 548-552.